Methods and apparatus for extrusion of vesicles at high pressure

• US 20050260256A1
• Filed: 09/27/2002
• Published: 11/24/2005
• Est. Priority Date: 09/28/2001
• Status: Abandoned Application

• Current Assignee: Pfizer Inc.
• Original Assignee: Pfizer Inc.
• Inventors: Hill, Knut R., Sy, Gavin A., Rodrigueza, Wendi
• Application Number:
  US10/256,767
• Publication Number:
  US 20050260256A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 9/1277 Processes for preparing; Proliposomes

Abstract

This invention relates in general to methods and devices for producing vesicles, including micelles, and particularly liposomes, by extruding solutions comprising materials capable of forming vesicles through a screen membrane at high pressure.

Claims

1. A method of producing a suspension of vesicles comprising extruding a mixture comprising a lipid through a hydrophilic screen membrane at high pressure.

2. The method of claim 1 wherein said suspension of vesicles is a suspension of liposomes.

3. The method of claim 1 wherein said mixture comprises a suspension of multilaminate vesicles.

4. The method of claim 1 wherein said mixture is an emulsion.

5. The method of claim 1 wherein said mixture comprises a plurality of lipids.

6. The method of claim 1 wherein said hydrophilic screen membrane has a water contact angle of about 70 degrees or less.

7. The method of claim 6 wherein said screen membrane has a water contact angle of about 50 degrees or less.

8. The method of claim 7 wherein said screen membrane has a water contact angle of about 40 degrees or less.

9. The method of claim 1 wherein said hydrophilic screen membrane comprises at least one material selected from the group consisting of polyester, aluminum oxide, cellulose acetate, cellulose mixed ester, glass, polyethersulfone, polyvinyl pyrolidine and polysulfone.

10. The method of claim 1 wherein said hydrophilic screen membrane is a polyester membrane.

11. The method of claim 1 wherein said hydrophilic screen membrane is a track-etched membrane.

12. The method of claim 1 wherein said hydrophilic screen membrane comprises a coating.

13. The method of claim 12 wherein said coating is a hydrophilic coating.

14. The method of claim 12 wherein said coating is a hydrophobic coating.

15. The method of claim 1 wherein said vesicles have an average diameter of between about 50 nm and 400 nm.

16. The method of claim 1 wherein said vesicles have an average diameter of between about 50 nm and 150 nm.

17. The method of claim 1 wherein said vesicles have an average diameter of between about 100 nm and 150 nm.

18. The method of claim 1 wherein said vesicles have an average diameter in the range of about 169±

37 nm.

19. The method of claim 1 wherein said vesicles have an average diameter in the range of about 158±

39.5 nm.

20. The method of claim 1 wherein said vesicles have an average diameter in the range of about 136±

42 nm.

21. The method of claim 1 wherein said vesicles have an average diameter in the range of about 153.6±

45.2 nm.

22. The method of claim 1 wherein said vesicles have an average diameter in the range of about 138.6±

35.6 nm.

23. The method of claim 1 wherein said vesicles have an average diameter in the range of about 114.4±

35.8 nm.

24. The method of claim 1 wherein said vesicles have an average diameter in the range of about 118.1±

36.2 nm.

25. The method of claim 1 wherein said lipid has a transition temperature at or below room temperature.

26. The method of claim 1 wherein said lipid has a transition temperature above room temperature.

27. The method of claim 1 wherein said lipid comprises a rigid acyl chain.

28. The method of claim 27 wherein said rigid acyl chain is a mono-unsaturated acyl chain.

29. The method of claim 1 wherein the mixture comprises impurities or contaminants.

30. The method of claim 1 wherein the lipid is a drug-associated lipid.

31. The method of claim 1 wherein the lipid is a charged lipid.

32. The method of claim 1 wherein the lipid is associated with a protein.

33. The method of claim 1 wherein said lipid is selected from the group consisting of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol di-stearoyl-phosphatidylethanolamine, egg yolk phosphatidylcholine, di-oleoyl-phosphatidylcholine, di-lauroylphosphatidylcholine, di-lauroylphosphatidylglycerol, oleoyl-palmitoylphosphatidylcholine, glycolipid-linked phospholipids, phosphatidylcholine, phosphatidylglycerol, lecithin, β

, γ

-dipalmitoyl-α

-lecithin, sphingomyelin, phosphatidylserine, phosphatidic acid, N-(2,3-di(9-(Z)-octadecenyloxy))-prop-1-yl-N,N,N-trimethylammonium chloride, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylinositol, cephalin, cardiolipin, cerebrosides, dicetylphosphate, di-oleoyl-phosphatidylglycerol, palmitoyl-oleoyl-phosphatidylcholine, di-stearoyl-phosphatidylcholine, stearoyl-palmitoyl-phosphatidylcholine, di-palmitoyl-phosphatidylethanolamine, di-stearoyl-phosphatidylethanolarnine, di-myrstoyl-phosphatidylserine and di-oleyl-phosphatidylcholine.

34. The method of claim 33 wherein the lipid is phosphatidylcholine or sphingomyelin.

35. The method of claim 1 wherein said hydrophilic screen membrane has an average pore diameter of about 0.4 μ

m or less.

36. The method of claim 35 wherein said hydrophilic screen membrane has an average pore diameter of about 0.2 μ

m or less.

37. The method of claim 36 wherein said hydrophilic screen membrane has an average pore diameter of about 0.1 μ

m or less.

38. The method of claim 1 wherein said extrusion is performed at a pressure of about 400 psi or greater.

39. The method of claim 38 wherein said extrusion is performed at a pressure of about 800 psi or greater.

40. The method of claim 39 wherein said extrusion is performed at a pressure of about 1,500 psi or greater.

41. The method of claim 40 wherein said extrusion is performed at a pressure of about 5,000 psi or greater.

42. The method of claim 41 wherein said extrusion is performed at a pressure of about 8,000 psi or greater.

43. The method of claim 42 wherein said aqueous suspension of lipids is extruded through a plurality of stacked membranes.

44. The method of claim 43 wherein each stacked membrane has the same average pore diameter.

45. The method of claim 44 wherein at least one stacked membrane has an average pore diameter different from the average pore diameter of at least one other stacked membrane.

46. The method of claim 45 wherein said stacked membranes are arranged so that said mixture is extruded through membranes of progressively smaller average pore size.

47. The method of claim 1 wherein said extrusion is conducted at a controlled temperature.

48. The method of claim 47 wherein said controlled temperature is approximately constant temperature.

49. The method of claim 48 wherein said approximately constant temperature is about room temperature.

50. The method of claim 49 wherein said approximately constant temperature is between about 20°

C. to about 30°

C.

51. The method of claim 50 wherein said approximately constant temperature is about 25°

C.

52. The method of claim 1 wherein said mixture is extruded through said hydrophilic membrane at a flux rate of between about 0.0001 and about 40 mL/min/mm².

53. The method of claim 1 wherein said vesicles comprise a pharmaceutically active substance.

54. The method of claim 1 wherein said extrusion comprises multiple passes.

55. The method of claim 54 wherein said extrusion comprises a step-down extrusion.

56. The method of claim 1 wherein said mixture is extruded through said hydrophilic screen membrane alternately in the forward and reverse directions.

57. The method of claim 1 wherein said hydrophilic screen membrane has a pore density greater than about 8×

10⁵ pores/cm².

58. The method of claim 1 wherein said hydrophilic screen membrane has a thickness of between about 3 and about 50 μ

m.

60. The method of claim 1 wherein said hydrophilic screen membrane is rinsed with a flushing agent prior to said extrusion.

61. The method of claim 60 wherein said flushing agent removes clogged or fouled material from said membrane'"'"'s pores.

62. The method of claim 60 wherein said flushing agent prevents clogged or fouled material from said membrane'"'"'s pores.

63. The method of claim 61 or 62 wherein said flushing agent comprises ethanol.

59. A device for extruding an aqueous suspension of lipids at high pressure comprising a hydrophilic screen membrane and means for entry and exit of liquid under high pressure.

64. A method of producing liposomes comprising extruding a mixture comprising a lipid through a hydrophilic membrane at pressures greater than about 8,000 psi.

65. The method of claim 64, wherein said vesicles have an average diameter of between about 50 nm and 400 nm.

66. The method of claim 64 herein the liposomes have an average diameter of between about 50 nm and 150 nm.

67. The method of claim 64 wherein the liposomes have an average diameter of between about 100 nm and 150 nm.

68. The method of claim 64 wherein said vesicles have an average diameter in the range of about 169±

37 nm.

69. The method of claim 64 wherein said vesicles have an average diameter in the range of about 158±

39.5 nm.

70. The method of claim 64 wherein said vesicles have an average diameter in the range of about 136±

42 nm.

71. The method of claim 64 wherein said vesicles have an average diameter in the range of about 153.6±

45.2 nm.

72. The method of claim 64 wherein said vesicles have an average diameter in the range of about 138.6±

35.6 nm.

73. The method of claim 64 wherein said vesicles have an average diameter in the range of about 114.4±

35.8 nm.

74. The method of claim 64 wherein said vesicles have an average diameter in the range of about 118.1±

36.2 nm.